Outlook Therapeutics, Inc. (OTLK)

7.13 -0.80 (-10.14%) 收市：04:00PM EDT

Outlook Therapeutics, Inc.

Building F
Suite 320 485 Route 1 South
Iselin, NJ 08852
United States
609 619 3990
https://www.outlooktherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 24

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Ralph H. Thurman	Independent Executive Chairman	207.5k	無	1949
Mr. C. Russell Trenary III	President, CEO & Director	610.9k	無	1958
Mr. Lawrence A. Kenyon CPA	Executive VP, CFO, Treasurer, Company Secretary & Director	無	無	1966
Mr. Jeffrey Evanson	Chief Commercial Officer	451.17k	無	1969
Ms. Alicia Tozier	Senior Vice President, Marketing & Market Access	無	無	無
Mr. Joel Prieve	Senior Vice President of Licensing and M&A	無	無	無
Dr. Surendra Sharma M.D.	Senior Vice President of Medical Affairs	無	無	無
Dr. Jennifer M. Kissner Ph.D.	Senior Vice President of Clinical Development & Regulatory Affairs	無	無	無
Mr. Jedd Comiskey	Senior VP - Head of Europe	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

公司管治

截至 2024年5月1日 止，Outlook Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：6；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。